Foreign companies hunt for buyouts in growing market with lower production costs.
India’s per capita healthcare expenditure is well below international recommendations and compares poorly with the other emerging economies (Brazil, Russian Federation, China, Republic of Korea, Turkey and Mexico). Despite an improvement in the country’s healthcare infrastructure over the recent past, there remains a lack of health centers and shortage of health personnel.
MORE than two dozen pharmaceutical companies are racing against the clock to test, produce and ship more than a billion doses of swine flu vaccines to anxious populations worldwide.
The North India based listed pharmaceutical companies have established strong presence in the domestic market, highly regulated markets and emerging markets during the last couple of years with several US FDA approved facilities, high-tech R&D laboratories, focus on new lifestyle drugs and partnership with international giants.
Delhi-based hospital chain Fortis Healthcare has acquired 10 hospitals from the Wockhardt stable for Rs 909 crore.
American consumer products major Procter & Gamble Company will be selling its global pharmaceuticals business to Ireland-based Pharma entity Warner Chilcott Plc for about USD 3.1 billion.
Swiss pharmaceutical giant F. Hoffmann–La Roche signed a deal with Israeli venture capital firm Pontifax Management Company for its first significant undertaking in the country to build up its R&D pipeline by way of investment in the Israeli life science industry.
Indian Pharmaceutical Alliance (IPA), the apex body representing domestic pharma companies, is up in arms against the government’proposed action plan to boost drug exports. The department of pharmaceuticals (DoP) has proposed funding by venture capitalists (VCs), service tax exemptions, import duty waiver on pharmaceutical products and protection to clinical test data to boost exports.
India emerging as a big global destination for contract manufacturing, unlike R&D outsourcing
GlaxoSmithKline Plc’s anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies, as the US Food and Drug Administration (FDA) has given almost half of the final approvals for the reverse engineered or generic versions of the drug made by Indian pharmaceutical companies, following its patent expiry.
x (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.
Sun Pharmaceutical Industries (SUN.BO) has got the U.S. Food and Drug Administration's approval to launch its generic version of GlaxoSmithKline's (GSK.L) Imitrex tablets to treat migraine, the Indian drugmaker said.
Despite the best efforts of Indian vaccine makers to develop the H1N1(swine flu) vaccine, Swiss drug major Novartis and Australian vaccine maker CSL may be the first ones to bag the orders from the central government for its supply.
All major industries are facing a tough ride with the current global financial conditions, but the pharmaceutical/biotech industry is taking steps to overcome this situation.
Cadila Pharmaceutical Limited, an Ahmedabad-based unlisted pharma major, hopes to be the first to launch the vaccine for swine flu virus H1N1 by November this year.
Low costs, high technical capabilities and a skilled work force are making India an attractive destination for research and contract manufacturing of drugs
Domestic demand, pro-generic regime boost sales.Company Revenue Growth (in %) Biocon 88 Cadila Healthcare 27 Cipla 13 Dr Reddys 21 Glenmark Pharma 18 Jubilant Organosys 8 Lupin 25 Piramal Healthcare 15 Ranbaxy 1 Sun Pharma -24Strong domestic demand, growing preference for generics worldwide and favourable rupee-dollar exchange rate helped the pharmaceutical sector post 11 per cent sales growth for the quarter ended June 2009, compared with the same period a year ago.
The pharmaceutical industry in India is likely to see added stimulus in coming months. The department of pharmaceuticals (DoP) has put forth a number of proposals to the government which will help boost the pharma sector in the country, said Ashok Kumar, secretary of DoP, on Saturday at the AGM of the Organisation of Pharmaceutical Producers of India (OPPI).
Sandoz today announced the introduction of tacrolimus capsules, a generic equivalent of Prograf®, in the US. Tacrolimus is an immunosuppressive treatment used to help prevent rejection of a kidney or liver transplant.
The cost advantage is luring many pharma companies to prefer India as the destination for contract research and clinical trials to the developed markets, according to a study.